Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Trinh A, Lädrach C, Dawson HE, Ten Hoorn S, Kuppen PJK, Reimers MS, Koopman M, Punt CJA, Lugli A, Vermeulen L, Zlobec I.

Br J Cancer. 2018 Nov 2. doi: 10.1038/s41416-018-0230-7. [Epub ahead of print]

PMID:
30385823
2.

Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients.

Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, IJzerman MJ, Koffijberg H.

Cancer Epidemiol. 2018 Oct 11;57:60-67. doi: 10.1016/j.canep.2018.09.008. [Epub ahead of print]

PMID:
30317148
3.

Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.

Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E, Tanis PJ, de Hingh IHJT, van der Schelling GP, Acherman Y, Leijtens JWA, Bremers AJA, Beets GL, Hoff C, Verhoef C, Marijnen CAM, de Wilt JHW; CARTS Study Group.

JAMA Surg. 2018 Oct 10. doi: 10.1001/jamasurg.2018.3752. [Epub ahead of print]

PMID:
30304338
4.

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.

Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6.

5.

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.

Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, Punt CJA, Koopman M, May AM.

J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):909-919. doi: 10.1002/jcsm.12337. Epub 2018 Aug 24.

6.

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands.

Uyl-de Groot CA, van Rooijen EM, Punt CJA, Pescott CP.

Health Econ Rev. 2018 Jul 17;8(1):13. doi: 10.1186/s13561-018-0197-3. Review.

7.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
8.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
9.

Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.

Goey KKH, Mahmoud R, Sørbye H, Glimelius B, Köhne CH, Sargent DJ, Punt CJA, van Oijen MGH, Koopman M.

Eur J Cancer. 2018 Jun;96:115-124. doi: 10.1016/j.ejca.2018.03.026. Epub 2018 May 2. Review.

PMID:
29729562
10.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

11.

Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M.

Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30.

PMID:
29353165
12.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

PMID:
29267900
13.

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJE, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJA, Koopman M.

Int J Clin Oncol. 2018 Jun;23(3):482-489. doi: 10.1007/s10147-017-1220-0. Epub 2017 Dec 4.

14.

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB.

J Clin Oncol. 2018 Jan 20;36(3):268-275. doi: 10.1200/JCO.2017.73.7718. Epub 2017 Nov 21.

PMID:
29161204
15.

Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group.

Keikes L, van Oijen MGH, Lemmens VEPP, Koopman M, Punt CJA.

Clin Colorectal Cancer. 2018 Mar;17(1):58-64. doi: 10.1016/j.clcc.2017.10.007. Epub 2017 Nov 20.

16.

Pseudoprogression on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer.

Punt CJA, Huiskens J, van Gulik T, Engelbrecht M.

Acta Oncol. 2018 May;57(5):681-682. doi: 10.1080/0284186X.2017.1374556. Epub 2017 Nov 15. No abstract available.

PMID:
29140135
17.

Does portal vein embolization prior to liver resection influence the oncological outcomes - A propensity score matched comparison.

Huiskens J, Olthof PB, van der Stok EP, Bais T, van Lienden KP, Moelker A, Krumeich J, Roumen RM, Grünhagen DJ, Punt CJA, van Amerongen M, de Wilt JHW, Verhoef C, Van Gulik TM.

Eur J Surg Oncol. 2018 Jan;44(1):108-114. doi: 10.1016/j.ejso.2017.09.017. Epub 2017 Sep 20.

PMID:
29126672
18.

Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.

Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, Arnold D, Koopman M.

Br J Cancer. 2017 Dec 5;117(12):1768-1776. doi: 10.1038/bjc.2017.382. Epub 2017 Nov 9.

PMID:
29123255
19.

Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.

Keikes L, Koopman M, Tanis PJ, Lemmens VEPP, Punt CJA, van Oijen MGH.

Eur J Cancer. 2017 Nov;86:166-177. doi: 10.1016/j.ejca.2017.08.034. Epub 2017 Oct 6. Review.

PMID:
28988017
20.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

21.

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.

Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, de Leng WWJ, Strengman E, Ten Tije AJ, Creemers GM, van der Velden A, de Jongh FE, Erdkamp FLG, Tanis BC, Punt CJA, Koopman M.

Ann Oncol. 2017 Sep 1;28(9):2128-2134. doi: 10.1093/annonc/mdx322.

PMID:
28911067
22.

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ.

Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.

23.

Colorectal cancer at high risk of peritoneal metastases: long term outcomes of a pilot study on adjuvant laparoscopic HIPEC and future perspectives.

Klaver CEL, Stam R, Sloothaak DAM, Crezee J, Bemelman WA, Punt CJA, Tanis PJ.

Oncotarget. 2017 Apr 17;8(31):51200-51209. doi: 10.18632/oncotarget.17158. eCollection 2017 Aug 1.

24.

Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review.

Engelhardt EG, Révész D, Tamminga HJ, Punt CJA, Koopman M, Onwuteaka-Philipsen BD, Steyerberg EW, Jansma IP, De Vet HCW, Coupé VMH.

Clin Colorectal Cancer. 2018 Mar;17(1):e1-e12. doi: 10.1016/j.clcc.2017.06.007. Epub 2017 Jun 24.

25.

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, van Laarhoven HWM; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group.

Acta Oncol. 2018 Feb;57(2):195-202. doi: 10.1080/0284186X.2017.1346381. Epub 2017 Jul 19.

PMID:
28723307
26.

The impact of data errors on the outcome of randomized clinical trials.

Buyse M, Squifflet P, Coart E, Quinaux E, Punt CJ, Saad ED.

Clin Trials. 2017 Oct;14(5):499-506. doi: 10.1177/1740774517716158. Epub 2017 Jun 22.

PMID:
28641461
27.

Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.

Kwakman JJM, Baars A, van Zweeden AA, de Mol P, Koopman M, Kok WEM, Punt CJA.

Eur J Cancer. 2017 Aug;81:130-134. doi: 10.1016/j.ejca.2017.05.022. Epub 2017 Jun 15. No abstract available.

PMID:
28623776
28.

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Versteijne E, Lens E, van der Horst A, Bel A, Visser J, Punt CJA, Suker M, van Eijck CHJ, van Tienhoven G.

Strahlenther Onkol. 2017 Aug;193(8):630-638. doi: 10.1007/s00066-017-1153-6. Epub 2017 Jun 12.

29.

Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review.

Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH.

Crit Rev Oncol Hematol. 2017 Jun;114:53-62. doi: 10.1016/j.critrevonc.2017.03.028. Epub 2017 Mar 24. Review.

PMID:
28477747
30.

Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study.

Lamkaddem M, Elferink MAG, Seeleman MC, Dekker E, Punt CJA, Visser O, Essink-Bot ML.

BMC Cancer. 2017 May 4;17(1):312. doi: 10.1186/s12885-017-3241-5.

31.

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A.

Ann Oncol. 2017 Sep 1;28(9):2077-2085. doi: 10.1093/annonc/mdx191. Review.

PMID:
28430862
32.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

33.

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.

Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJM, Hendriks MP, Los M, van Alphen RJ, Polée MB, Muller EW, van der Velden AMT, van Voorthuizen T, Koopman M, Mol L, van Werkhoven E, Punt CJA.

Ann Oncol. 2017 Jun 1;28(6):1288-1293. doi: 10.1093/annonc/mdx122.

PMID:
28383633
34.

Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx015.

35.

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.

Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ.

Eur J Cancer. 2017 May;76:93-99. doi: 10.1016/j.ejca.2017.02.009. Epub 2017 Mar 10.

PMID:
28286287
36.

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.

Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, Mol L, Ten Tije AJ, Creemers GJ, van der Velden AMT, Tanis BC, Uyl-de Groot CA, Punt CJA, Koopman M, van Oijen MGH.

Eur J Cancer. 2017 Apr;75:204-212. doi: 10.1016/j.ejca.2017.01.019. Epub 2017 Feb 24.

PMID:
28237866
37.

Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.

Rovers KP, Simkens GA, Vissers PA, Lemmens VE, Verwaal VJ, Bremers AJ, Wiezer MJ, Burger JW, Hemmer PH, Boot H, van Grevenstein WM, Meijerink WJ, Aalbers AG, Punt CJ, Tanis PJ, de Hingh IH; Dutch Peritoneal Oncology Group (DPOG).

Eur J Cancer. 2017 Apr;75:132-140. doi: 10.1016/j.ejca.2016.12.034. Epub 2017 Feb 20.

PMID:
28222307
38.

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.

Kwakman JJM, Baars A, Boot H, Pruijt JFM, Winther SB, Pfeiffer P, Punt CJA.

Acta Oncol. 2017 Jul;56(7):1023-1026. doi: 10.1080/0284186X.2016.1278459. Epub 2017 Jan 19. No abstract available.

PMID:
28102094
39.

Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy.

Olthof PB, Huiskens J, Wicherts DA, Huespe PE, Ardiles V, Robles-Campos R, Adam R, Linecker M, Clavien PA, Koopman M, Verhoef C, Punt CJ, van Gulik TM, de Santibanes E.

Surgery. 2017 Apr;161(4):909-919. doi: 10.1016/j.surg.2016.10.032. Epub 2016 Dec 27.

PMID:
28038862
40.

Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands.

't Lam-Boer J, van der Stok EP, Huiskens J, Verhoeven RH, Punt CJ, Elferink MA, de Wilt JH, Verhoef C; CAIRO5/CHARISMA Group.

Eur J Cancer. 2017 Jan;71:109-116. doi: 10.1016/j.ejca.2016.10.026. Epub 2016 Dec 16.

PMID:
27988444
41.

From tumour heterogeneity to advances in precision treatment of colorectal cancer.

Punt CJ, Koopman M, Vermeulen L.

Nat Rev Clin Oncol. 2017 Apr;14(4):235-246. doi: 10.1038/nrclinonc.2016.171. Epub 2016 Dec 6. Review.

PMID:
27922044
42.

Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.

Goey KK, 't Lam-Boer J, de Wilt JH, Punt CJ, van Oijen MG, Koopman M.

Eur J Cancer. 2016 Dec;69:166-177. doi: 10.1016/j.ejca.2016.09.028. Epub 2016 Nov 5. Review.

PMID:
27821320
43.

Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer.

Agasi-Idenburg SC, Thong MS, Punt CJ, Stuiver MM, Aaronson NK.

Support Care Cancer. 2017 Feb;25(2):625-632. doi: 10.1007/s00520-016-3451-4. Epub 2016 Oct 21.

PMID:
27770205
44.

Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions.

Ter Voert EE, Heijmen L, Punt CJ, de Wilt JH, van Laarhoven HW, Heerschap A.

NMR Biomed. 2016 Nov;29(11):1526-1535. doi: 10.1002/nbm.3606. Epub 2016 Sep 6.

PMID:
27598946
45.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group.

Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12.

PMID:
27743922
46.

Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer.

Engelhardt EG, Pieterse AH, Han PK, van Duijn-Bakker N, Cluitmans F, Maartense E, Bos MM, Weijl NI, Punt CJ, Quarles van Ufford-Mannesse P, Sleeboom H, Portielje JE, van der Hoeven KJ, Woei-A-Jin FJ, Kroep JR, de Haes HC, Smets EM, Stiggelbout AM.

Med Decis Making. 2017 Apr;37(3):179-192. doi: 10.1177/0272989X16670639. Epub 2016 Sep 29.

PMID:
27681991
47.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ.

Oncoimmunology. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732. eCollection 2016 Jul.

48.

The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.

Mol L, Ottevanger PB, Koopman M, Punt CJ.

Eur J Cancer. 2016 Oct;66:138-43. doi: 10.1016/j.ejca.2016.07.013. Epub 2016 Aug 26.

PMID:
27573427
49.

Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research.

Burbach JP, Kurk SA, Coebergh van den Braak RR, Dik VK, May AM, Meijer GA, Punt CJ, Vink GR, Los M, Hoogerbrugge N, Huijgens PC, Ijzermans JN, Kuipers EJ, de Noo ME, Pennings JP, van der Velden AM, Verhoef C, Siersema PD, van Oijen MG, Verkooijen HM, Koopman M.

Acta Oncol. 2016 Nov;55(11):1273-1280. Epub 2016 Aug 25.

PMID:
27560599
50.

[Local approval procedures act as a brake on RCTs].

van der Stok EP, Huiskens J, Hemmes B, Grünhagen DJ, van Gulik TM, Verhoef C, Punt CJ.

Ned Tijdschr Geneeskd. 2016;160:D148. Dutch.

PMID:
27552934

Supplemental Content

Support Center